Cosnarovici Maria Margareta, Piciu Andra, Bonci Eduard-Alexandru, Bădan Marius-Ioan, Bădulescu Claudiu-Iulian, Stefan Andreea-Ioana, Mester Alexandru, Cosnarovici Rodica, Larg Maria-Iulia
Department of Medical Oncology Iuliu Hațieganu, University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Department of Surgical Oncology Iuliu Hațieganu, University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Diagnostics (Basel). 2020 Mar 5;10(3):142. doi: 10.3390/diagnostics10030142.
The purpose of the study was to evaluate the association of thyroid dysfunction occurring in pediatric patients treated for brain tumors.
A total of 255 patients with brain tumors were treated between 2001 and 2018 at the "Prof. Dr. Ion Chiricuță" Institute of Oncology, Cluj-Napoca. Due to a minimum follow-up of 4 years, we studied 184 out of the 255 patients. The cohort included 69 girls (37.5%) and 109 boys (62.5%), with a median age of 8.4 years. The evaluated tumors included medulloblastomas (47 patients), astrocytomas (44 patients), ependymomas (22 patients), gliomas (20 patients), germ cell tumors (12 patients), primitive neuroectodermal tumors (4 patients), as well as other types of tumors (15 patients); in 20 of the cases, biopsy could not be performed.
There was a 60% overall survival rate; among the 120 surviving patients, 11 (9.1%) were diagnosed with iatrogenic thyroid disease. We observed an important number of iatrogenic thyroid disease cases in this group of patients, thus revealing the importance of long-term thyroid function evaluation in all children who finalized their treatment for brain tumors. Through this study, we aimed to provide an accurate image of the methodology of monitoring for thyroid dysfunction in childhood brain tumor survivors.
Given the fact that the probability of developing thyroid dysfunction in the pediatric population treated for brain tumors is not rare, we recommend that childhood brain tumor survivors be monitored for iatrogenic thyroid disease, in order to provide early diagnosis and treatment.
本研究旨在评估接受脑肿瘤治疗的儿科患者中发生的甲状腺功能障碍之间的关联。
2001年至2018年间，共有255例脑肿瘤患者在克卢日-纳波卡的“伊翁·基里库察教授”肿瘤研究所接受治疗。由于至少随访4年，我们对255例患者中的184例进行了研究。该队列包括69名女孩（37.5%）和109名男孩（62.5%），中位年龄为8.4岁。评估的肿瘤包括髓母细胞瘤（47例）、星形细胞瘤（44例）、室管膜瘤（22例）、神经胶质瘤（20例）、生殖细胞瘤（12例）、原始神经外胚层肿瘤（4例）以及其他类型的肿瘤（15例）；其中20例无法进行活检。
总生存率为６０％；在120名存活患者中，11例（9.1%）被诊断为医源性甲状腺疾病。我们在这组患者中观察到大量医源性甲状腺疾病病例，从而揭示了对所有完成脑肿瘤治疗的儿童进行长期甲状腺功能评估的重要性。通过本研究，我们旨在提供儿童脑肿瘤幸存者甲状腺功能障碍监测方法的准确情况。
鉴于接受脑肿瘤治疗的儿科人群发生甲状腺功能障碍的可能性并不罕见，我们建议对儿童脑肿瘤幸存者进行医源性甲状腺疾病监测，以便早期诊断和治疗。
